Search Results

BrainsWay Ltd., a world leader in advanced and non-invasive treatment for brain disorders, reported first quarter 2024 financial results and provided an operational update.

BrainsWay Ltd. today announced that it will report its first quarter 2024 financial results as well as operational highlights before the open of the U.S. financial markets on Wednesday, May 8, 2024.

BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its fourth quarter and full year 2023 financial results as well as operational highlights before the open of the U.S. financial markets on Wednesday, March 6, 2024.

BrainsWay Ltd., a world leader in advanced and non-invasive treatment for brain disorders, reported fourth quarter and full-year 2023 financial results and provided an operational update.

BrainsWay Ltd. today announced that the US Food and Drug Administration (FDA) has granted an expanded indication for the Company’s Deep Transcranial Magnetic Stimulation system (Deep TMS™) allowing for the treatment of patients with major depressive disorder (MDD) ages 22 to 86.